Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!

Easy Branches

34/17 Moo 3 Chao fah west Road, Phuket, Thailand, Phuket

Call: 076 367 766

info@easybranches.com

Financial Personal

Sabadell Plans Risk Transfer Linked to $1.3 Billion Loans

Banco Sabadell SA, the Spanish lender seeking to fend off a takeover from a rival, is reaching out to potential investors to offload credit risk linked to a portfolio of about $1.3 billion of loans.

By: financialpost.com

Oct 09 2024
0
0 Views

Sabadell Plans Risk Transfer Linked to $1.3 Billion Loans

(Bloomberg) — Banco Sabadell SA, the Spanish lender seeking to fend off a takeover from a rival, is reaching out to potential investors to offload credit risk linked to a portfolio of about $1.3 billion of loans. Read More

Related

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

TC Energy announces expiration and upsizing of cash tender offers for certain Canadian-dollar denominated debt securities

TC Energy announces upsizing and results of its cash tender offers

Brookfield Asset Management to Host Third Quarter 2024 Results Conference Call

Couche-Tard sweetens offer for 7-Eleven owner to $47 billion

Bitget Integrates GMCI Indices Enabling Curated-Secured Trading

Boeing withdraws contract offer after talks with striking workers break down

Sabadell Plans Risk Transfer Linked to $1.3 Billion Loans

Hiring managers and job seekers are caught in a vicious cycle

Nobel Prize in chemistry awarded to David Baker, Demis Hassabis and John Jumper for work on proteins

Ottawa Climate Action Fund Convenes Industry and Business Leaders in Landmark Housing Summit

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Next

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients